Positive Brilacidin UP trial will add value to a potential partner in that is shows usage in inflammatory diseases in addition to antibiotic usage. This really is a big deal for value of potential partnership or licensing deal for the platform.
You might be partially correct about it taking a long time to see increase in share price if the company intended to take all of the drugs to approval on their own. But, they aren't. They've made it clear they are seeking partners.
The question is which asset gets partnered first?
In Reply to 'To infinity and beyond!'
Fine then
I am wrong you and others say
So how much then will it be worth? Let's say that Leo says 10 of 16 patients, in whatever country they happen to inhabit, have improvement of disease based on sigmoidoscopy.
How much more will CTIX be worth?
I say little or no increase in share price or value to a partner.
What do you think?
Recent 2A Prurisol showed some positive results and the share price went.....down.
News 
Market Data 
Discover 
AI
